Europe Antimicrobial Susceptibility Testing Market - Indsutry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 65
1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 65
1.4 LIMITATIONS 67
1.5 MARKETS COVERED 67
2 MARKET SEGMENTATION 70
2.1 MARKETS COVERED 70
2.2 GEOGRAPHICAL SCOPE 71
2.3 YEARS CONSIDERED FOR THE STUDY 72
2.4 CURRENCY AND PRICING 72
2.5 DBMR TRIPOD DATA VALIDATION MODEL 73
2.6 MULTIVARIATE MODELLING 76
2.7 PRODUCT TYPE LIFELINE CURVE 77
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.9 DBMR MARKET POSITION GRID 79
2.10 MARKET APPLICATION COVERAGE GRID 80
2.11 VENDOR SHARE ANALYSIS 81
2.12 SECONDARY SOURCES 82
2.13 ASSUMPTIONS 82
3 EXECUTIVE SUMMARY 83
4 PREMIUM INSIGHTS 85
5 MARKET OVERVIEW 86
5.1 DRIVERS 88
5.1.1 RISING EPIDEMIC AND PANDEMIC OUTBREAK 88
5.1.2 GROWING HEALTHCARE EXPENDITURE 88
5.1.3 INCREASING EUROPE PREVALENCE OF INFECTIOUS DISEASES 89
5.1.4 INCREASING PREVALENCE OF MULTI-DRUG RESISTANCE ORGANISM 89
5.1.5 GROWING INFRASTRUCTURE FACILITIES 89
5.1.6 HIGHER ADOPTION OF TECHNOLOGICALLY ADVANCED SUSCEPTIBILITY TESTING METHODS 90
5.2 RESTRAINTS 90
5.2.1 STRINGENT GOVERNMENT REGULATIONS 90
5.2.2 HIGH COSTS 91
5.2.3 SHORTAGE OF SKILLED PERSONNEL 91
5.3 OPPORTUNITIES 92
5.3.1 TECHNOLOGICAL ADVANCEMENTS 92
5.3.2 INVESTMENTS IN HEALTHCARE INFRASTRUCTURE 92
5.3.3 INFRASTRUCTURE OF NEW GENOMIC IDENTIFICATION METHODS 93
5.3.4 INCREASE IN FUNDING 93
5.4 CHALLENGES 94
5.4.1 EMERGENCE OF LOCAL PLAYER IN THE MARKETS 94
5.4.2 LACK OF CLINICAL DATA FROM FDA 94
5.4.3 DELAYS BETWEEN CLINICAL BREAKPOINT AND ITS CLEARANCE 94
6 IMPACT OF COVID-19 ON EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 95
6.1 IMPACT ON PRICE 95
6.2 IMPACT ON DEMAND 95
6.3 IMPACT ON SUPPLY 95
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 96
6.5 CONCLUSION: 96
7 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE 97
7.1 OVERVIEW 98
7.2 INSTRUMENTS 101
7.2.1 MANUAL 102
7.2.1.1 MINIATURIZED IDENTIFICATION SYSTEMS 102
7.2.1.2 SUSCEPTIBILITY TESTING DISCS 102
7.2.1.2.1 HEXA DISCS 103
7.2.1.2.1.1 GRAM NEGATIVE ORGANISM 103
7.2.1.2.1.2 GRAM POSITIVE ORGANISM 104
7.2.1.2.1.3 GENERAL PURPOSE 104
7.2.1.2.1.4 ANAEROBIC BACTERIA 104
7.2.1.2.1.5 ANTIFUNGAL 104
7.2.1.2.1.6 OTHERS 104
7.2.1.2.2 OCTA DISCS 104
7.2.1.2.2.1 GRAM NEGATIVE ORGANISM 105
7.2.1.2.2.2 GRAM POSITIVE ORGANISM 105
7.2.1.2.2.3 UTI ORGANISMS 105
7.2.1.2.2.4 PSEUDOMONAS 105
7.2.1.2.2.5 GENERAL PURPOSE 105

7.2.1.2.3 DODECA DISCS 106
7.2.1.2.3.1 GENERAL PURPOSE 106
7.2.1.2.3.2 GRAM NEGATIVE ORGANISM 106
7.2.1.2.3.3 GRAM POSITIVE ORGANISM 106
7.2.1.2.3.4 PSEUDOMONAS 106
7.2.1.2.3.5 UTI ORGANISMS 107
7.2.1.2.4 ICOSA DISCS 107
7.2.1.2.4.1 GENERAL PURPOSE 107
7.2.1.2.4.2 PSEUDOMONAS 107
7.2.1.2.4.3 UTI ORGANISMS 107
7.2.1.3 MIC STRIPS 107
7.2.1.3.1 COMBINATION ANTIBACTERIAL 108
7.2.1.3.2 DUAL ANTIBACTERIAL 108
7.2.1.3.3 MULTIPLE ANTIBACTERIAL 108
7.2.1.3.4 SINGLE ANTIBACTERIAL 108
7.2.1.3.5 ANTIFUNGAL 108
7.2.2 AUTOMATED IDENTIFICATION AND SUSCEPTIBILITY TESTING SYSTEM 108
7.3 CONSUMABLES & ACCESSORIES 109
7.3.1 REAGENT AND BROTHS 110
7.3.2 MEDIA 110
7.3.3 SUSCEPTIBILITY PANELS 110
7.3.4 OTHERS 110
7.4 SERVICES & SOFTWARE 110
8 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,BY METHOD 112
8.1 OVERVIEW 113
8.2 DISK DIFFUSION 116
8.3 DILUTION 116
8.4 MASS SPECTROMETRY METHOD 117
8.5 E-TESTS 117
8.6 GENOTYPIC METHODS 118
8.7 OTHERS 119
9 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 120
9.1 OVERVIEW 121
9.2 ANTIBACTERIAL TESTING 124
9.3 ANTIFUNGAL TESTING 124
9.4 OTHERS 125

10 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 126
10.1 OVERVIEW 127
10.2 CLINICAL DIAGNOSTICS 130
10.3 DRUG DISCOVERY AND DEVELOPMENT 131
10.4 EPIDEMIOLOGY 131
10.5 OTHERS 132
11 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 134
11.1 OVERVIEW 135
11.2 HOSPITALS 138
11.3 DIAGNOSTIC LABORATORIES 139
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 140
11.5 CONTRACT RESEARCH ORGANISATION 140
11.6 RESEARCH CENTRES & ACADEMIC INSTITUTES 142
11.7 OTHERS 142
12 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY DISTRIBUTION CHANNEL 145
12.1 OVERVIEW 146
12.2 DIRECT SALES 149
12.3 RETAIL SALES 150
12.4 THIRD PARTY DISTRIBUTOR 150
13 EUROPE ANTIMICROBIAL SUCEPTIBILITY TESTING MARKET BY GEOGRAPHY 152
13.1 OVERVIEW 152
13.2 EUROPE 156
13.2.1 GERMANY 166
13.2.2 FRANCE 171
13.2.3 U.K. 176
13.2.4 ITALY 181
13.2.5 SPAIN 186
13.2.6 RUSSIA 191
13.2.7 SWITZERLAND 196
13.2.8 NETHERLANDS 201
13.2.9 TURKEY 206
13.2.10 BELGIUM 211
13.2.11 REST OF EUROPE 216
14 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY LANDSCAPE 217
14.1 COMPANY SHARE ANALYSIS: EUROPE 217
15 SWOT 218
16 COMPANY PROFILE 219
16.1 THERMO FISHER SCIENTIFIC INC. 219
16.1.1 COMPANY SNAPSHOT 219
16.1.2 REVENUE ANALYSIS 219
16.1.3 COMPANY SHARE ANALYSIS 220
16.1.4 PRODUCT PORTFOLIO 220
16.1.5 RECENT DEVELOPMENTS 221
16.2 BIOMRIEUX SA 222
16.2.1 COMPANY SNAPSHOT 222
16.2.2 REVENUE ANALYSIS 222
16.2.3 COMPANY SHARE ANALYSIS 223
16.2.4 PRODUCT PORTFOLIO 223
16.2.5 RECENT DEVELOPMENTS 223
16.3 DANAHER 225
16.3.1 COMPANY SNAPSHOT 225
16.3.2 REVENUE ANALYSIS 225
16.3.3 COMPANY SHARE ANALYSIS 226
16.3.4 PRODUCT PORTFOLIO 226
16.3.5 RECENT DEVELOPMENTS 227
16.4 MERCK KGAA 229
16.4.1 COMPANY SNAPSHOT 229
16.4.2 REVENUE ANALYSIS 229
16.4.3 COMPANY SHARE ANALYSIS 230
16.4.4 PRODUCT PORTFOLIO 230
16.4.5 RECENT DEVELOPMENTS 230
16.5 ACCELERATE DIAGNOSTICS, INC. 232
16.5.1 COMPANY SNAPSHOT 232
16.5.2 REVENUE ANALYSIS 232
16.5.3 PRODUCT PORTFOLIO 233
16.5.4 RECENT DEVELOPMENTS 233
16.6 ALIFAX S.R.L. 234
16.6.1 COMPANY SNAPSHOT 234
16.6.2 PRODUCT PORTFOLIO 234
16.6.3 RECENT DEVELOPMENTS 235
16.7 BACTERIOSCAN, INC. 236
16.7.1 COMPANY SNAPSHOT 236
16.7.2 PRODUCT PORTFOLIO 236
16.7.3 RECENT DEVELOPMENTS 236
16.8 BD 238
16.8.1 COMPANY SNAPSHOT 238
16.8.2 REVENUE ANALYSIS 238
16.8.3 PRODUCT PORTFOLIO 239
16.8.4 RECENT DEVELOPMENTS 239
16.9 BIO-RAD LABORATORIES, INC. 241
16.9.1 COMPANY SNAPSHOT 241
16.9.2 REVENUE ANALYSIS 241
16.9.3 PRODUCT PORTFOLIO 242
16.9.4 RECENT DEVELOPMENTS 242
16.10 CREATIVE DIAGNOSTICS 243
16.10.1 COMPANY SNAPSHOT 243
16.10.2 PRODUCT PORTFOLIO 243
16.10.3 RECENT DEVELOPMENTS 243
16.11 ERBA GROUP 245
16.11.1 COMPANY SNAPSHOT 245
16.11.2 PRODUCT PORTFOLIO 245
16.11.3 RECENT DEVELOPMENTS 245
16.12 GENEFLUIDICS, INC. 247
16.12.1 COMPANY SNAPSHOT 247
16.12.2 PRODUCT PORTFOLIO 247
16.12.3 RECENT DEVELOPMENTS 247
16.13 HIMEDIA LABORATORIES 249
16.13.1 COMPANY SNAPSHOT 249
16.13.2 PRODUCT PORTFOLIO 249
16.13.3 RECENT DEVELOPMENTS 249
16.14 LIOFILCHEM S.R.L. 251
16.14.1 COMPANY SNAPSHOT 251
16.14.2 PRODUCT PORTFOLIO 251
16.14.3 RECENT DEVELOPMENTS 251
16.15 MAST GROUP LTD. 253
16.15.1 COMPANY SNAPSHOT 253
16.15.2 PRODUCT PORTFOLIO 253
16.15.3 RECENT DEVELOPMENTS 253

16.16 MERLIN GESELLSCHAFT FUR MICROBIOLOGISCHE DIAGNOSTIKA MBH 255
16.16.1 COMPANY SNAPSHOT 255
16.16.2 PRODUCT PORTFOLIO 255
16.16.3 RECENT DEVELOPMENTS 255
16.17 NUMEDII, INC. 257
16.17.1 COMPANY SNAPSHOT 257
16.17.2 TECHNOLOGY PORTFOLIO 257
16.17.3 RECENT DEVELOPMENTS 257
16.18 ROSCO DIAGNOSTICA A/S 259
16.18.1 COMPANY SNAPSHOT 259
16.18.2 PRODUCT PORTFOLIO 259
16.18.3 RECENT DEVELOPMENT 259
16.19 SYNBIOSIS 260
16.19.1 COMPANY SNAPSHOT 260
16.19.2 PRODUCT PORTFOLIO 260
16.19.3 RECENT DEVELOPMENTS 260
16.20 ZHUHAI DL BIOTECH CO., LTD 262
16.20.1 COMPANY SNAPSHOT 262
16.20.2 PRODUCT PORTFOLIO 262
16.20.3 RECENT DEVELOPMENT 262
17 QUESTIONNAIRE 263
18 RELATED REPORTS 266